The third one is deemed to have passed the consistency evaluation
-
Last Update: 2019-11-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On November 11, Kelun pharmaceutical announced that the company had recently obtained the approval document for drug registration of the chemical "apixaban tablets" approved and issued by the State Drug Administration, which was deemed to have passed the consistency evaluation This is the third enterprise in China to pass the consistency evaluation after hausen and Zhengda Tianqing Apixaban, originally developed as Bristol Myers Squibb and Pfizer, is mainly used in adult patients undergoing selective hip or knee replacement to prevent venous thromboembolism (VTE) Apixaban is a reversible and highly selective direct XA factor inhibitor, which belongs to a new type of oral anticoagulant Compared with other commonly used anticoagulants such as warfarin, apixaban has good safety and tolerance, wide treatment window, and can effectively reduce the incidence of cerebral apoplexy and systemic embolism without increasing the risk of bleeding It has less interaction with food, fixed dose, and no need for routine hematology monitoring, so it is more convenient to use Chinese expert guide for prevention and treatment of tumor related venous thromboembolism (2015 Edition), Chinese guide for prevention of surgical venous thromboembolism of orthopaedic University and other authoritative domestic guidelines recommend factor Xa inhibitor apixaban to prevent venous thromboembolism 37
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
